RG7386, a novel tetravalent FAP-DR5 antibody, effectively triggers FAP-dependent, avidity-driven DR5 hyperclustering and tumor cell apoptosis

Molecular Cancer Therapeutics

Volumn 15, Issue 5, 2016, Pages 946-957

  Brünker, Peter ^a   Wartha, Katharina ^b,e   Friess, Thomas ^b   Grau Richards, Sandra ^a   Waldhauer, Inja ^a   Koller, Claudia Ferrara ^a   Weiser, Barbara ^b   Majety, Meher ^b   Runza, Valeria ^b   Niu, Huifeng ^c,f   Packman, Kathryn ^c,g   Feng, Ningping ^c,h   Daouti, Sherif ^c,i   Hosse, Ralf J ^a   Mössner, Ekkehard ^a   Weber, Thomas G ^b,j   Herting, Frank ^b   Scheuer, Werner ^b   Sade, Hadassah ^b   Shao, Cuiying ^d   Liu, Bin ^d   Wang, Peng ^d,k   Xu, Gary ^d   Vega Harring, Suzana ^b   Klein, Christian ^a   Bosslet, Klaus ^b   Umaña, Pablo ^a   more..

^a Roche Innovation Center Zurich   (Switzerland)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

^c Roche Innovation Center New York   (United States)

^d Roche Innovation Center Shanghai   (China)

^e ACTELION PHARMACEUTICALS LTD   (Switzerland)

^f TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^g Pharmaceutical Companies of Johnson and Johnson   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k CARsgen Therapeutics   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; DEATH RECEPTOR 5; DOXORUBICIN; DROZITUMAB; FC RECEPTOR; IRINOTECAN; RG 7386; SEPRASE; UNCLASSIFIED DRUG; GELATINASE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PROTEIN BINDING; SERINE PROTEINASE; TNFRSF10B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CROSS LINKING; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR AFFINITY; STROMA; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; ANTIBODY AFFINITY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; FIBROBLAST; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; GELATINASES; HUMANS; MEMBRANE PROTEINS; MICE; PROTEIN BINDING; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SERINE ENDOPEPTIDASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84969540602     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0647     Document Type: Article

References (47)

1. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8.
2. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487-501.
3. Wilson NS, Yang A, Yang B, Couto S, Stern H, Gogineni A, et al. Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth. Cancer Cell 2012;22:80-90.
4. Yang A, Wilson NS, Ashkenazi A. Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr Opin Cell Biol 2010; 22:837-44.
5. Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 2010;16:5883-91.
6. Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ Jr., RochaLima CM, et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol 2012;23:2834-42.
7. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 2010;16:1701-8.
8. Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 2008;15:751-61.
9. Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H, et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 2001; 166:4891-8.
10. Motoki K, Mori E, Matsumoto A, Thomas M, Tomura T, Humphreys R, et al. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res 2005;11: 3126-35.
11. Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, et al. Induction of tumor-specific T-cell immunity by anti-DR5 antibody therapy. J Exp Med 2004;199:437-48.
12. Kim JM, Ashkenazi A. Fcgamma receptors enable anticancer action of proapoptotic and immune-modulatory antibodies. J Exp Med 2013; 210:1647-51.
13. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011;19:101-13.
14. Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther 2012;11:257-66.
15. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A 1990;87:7235-9.
16. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Ozer HL, Schwab M, et al. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res 1993;53:3327-35.
17. Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011;108: 11187-92.
18. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007;449:101-4.
19. Weber TG, Osl F, Renner A, Poschinger T, Galban S, Rehemtulla A, et al. Apoptosis imaging for monitoring DR5 antibody accumulation and pharmacodynamics in brain tumors noninvasively. Cancer Res 2014; 74:1913-23.
20. Weber TG, Poschinger T, Galban S, Rehemtulla A, Scheuer W. Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with doxorubicin. Neoplasia 2013;15:863-74.
21. Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617-21.
22. Marconi M, Ascione B, Ciarlo L, Vona R, Garofalo T, Sorice M, et al. Constitutive localization of DR4 in lipid rafts is mandatory for TRAILinduced apoptosis in B-cell hematologic malignancies. Cell Death Dis 2013;4:e863.
23. Xu Y, Szalai AJ, Zhou T, Zinn KR, Chaudhuri TR, Li X, et al. Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol 2003;171:562-8.
24. Li F, Ravetch JV. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcgamma receptor engagement. Proc Natl Acad Sci U S A 2012;109:10966-71.
25. Kaplan-Lefko PJ, Graves JD, Zoog SJ, Pan Y, Wall J, Branstetter DG, et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther 2010;9:618-31.
26. Doi T, Murakami H, Ohtsu A, Fuse N, Yoshino T, Yamamoto N, et al. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2011;68:733-41.
27. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007;13:6187-94.
28. Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, et al. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 2010; 21:376-81.
29. Fay F, McLaughlin KM, Small DM, Fennell DA, Johnston PG, Longley DB, et al. Conatumumab (AMG 655) coated nanoparticles for targeted proapoptotic drug delivery. Biomaterials 2011;32:8645-53.
30. Gieffers C, Kluge M, Merz C, Sykora J, Thiemann M, Schaal R, et al. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcgamma receptors. Mol Cancer Ther 2013;12:2735-47.
31. Allen JE, Ferrini R, Dicker DT, Batzer G, Chen E, Oltean DI, et al. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Mol Cancer Ther 2012;11:2087-95.
32. Huet HA, Growney JD, Johnson JA, Li J, Bilic S, Ostrom L, et al. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction. MAbs 2014;6: 1560-70.
33. Swers JS, Grinberg L, Wang L, Feng H, Lekstrom K, Carrasco R, et al. Multivalent scaffold proteins as superagonists of TRAIL receptor 2-induced apoptosis. Mol Cancer Ther 2013;12:1235-44.
34. Papadopoulos KP, Isaacs R, Bilic S, Kentsch K, Huet HA, Hofmann M, et al. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody(R) targeting the DR5 receptor. Cancer Chemother Pharmacol 2015;75:887-95.
35. de Bruyn M, Rybczynska AA, Wei Y, Schwenkert M, Fey GH, Dierckx RA, et al. Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Mol Cancer 2010;9:301-14.
36. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001;7:383-5.
37. Siegemund M, Pollak N, Seifert O, Wahl K, Hanak K, Vogel A, et al. Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. Cell Death Dis 2012;3:e295.
38. Spitzer D, McDunn JE, Plambeck-Suess S, Goedegebuure PS, Hotchkiss RS, Hawkins WG. A genetically encoded multifunctional TRAIL trimer facilitates cell-specific targeting and tumor cell killing. Mol Cancer Ther 2010; 9:2142-51.
39. Stuckey DW, Shah K. TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med 2013;19:685-94.
40. Hewitt RE, Powe DG, Carter GI, Turner DR. Desmoplasia and its relevance to colorectal tumour invasion. Int J Cancer 1993;53:62-9.
41. Pandol S, Edderkaoui M, Gukovsky I, Lugea A, Gukovskaya A. Desmoplasia of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol 2009;7:S44-7.
42. Ronnov-Jessen L, Petersen OW, Bissell MJ. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 1996;76:69-125.
43. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002;8:2912-23.
44. Lee JM, Bernstein A. Apoptosis, cancer, and the p53 tumour suppressor gene. Cancer Metastasis Rev 1995;14:149-61.
45. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994;22:3551-5.
46. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002;2:277-88.
47. Galligan L, Longley DB, McEwan M, Wilson TR, McLaughlin K, Johnston PG. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther 2005;4:2026-36.